Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

ATACAND 32 MG TABLET

Candesartan Cilexetil
$9.8750per EA
High Outlier

Strength

32 mg/1

Manufacturer

ANI Pharmaceuticals, Inc.

NDC

62559064390

Classification

Brand

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

CANDESARTAN CILEXETIL

Approval Type

New Drug (NDA)

FDA Application

NDA020838

On Market Since

10/1/2018

Pharmacological Classes

Angiotensin 2 Receptor Antagonists
Angiotensin 2 Receptor Blocker

Price History

1W

0.0%

1M

+0.0%

3M

-0.1%

6M

-0.0%

1Y

+0.1%

3Y

N/A

5Y

N/A

All

+0.3%

Generic Alternatives

1 alternative • Same active ingredient

ATACAND 32 MG TABLET
Brand
62559064330•ANI Pharmaceuticals, Inc.
$9.8750

Related Drugs

Same classification

COZAAR 25 MG TABLET
Brand
78206012101•Organon LLC
$3.3620
per EA
MICARDIS HCT 80-12.5 MG TABLET
Brand
00597004437•Boehringer Ingelheim Pharmaceuticals Inc.
$4.4761
per EA
MICARDIS HCT 80-25 MG TABLET
Brand
00597004237•Boehringer Ingelheim Pharmaceuticals Inc.
$4.4768
per EA
MICARDIS 80 MG TABLET
Brand
00597004137•Boehringer Ingelheim Pharmaceuticals Inc.
$4.4823
per EA
MICARDIS HCT 40-12.5 MG TABLET
Brand
00597004337•Boehringer Ingelheim Pharmaceuticals Inc.
$4.4995
per EA
MICARDIS 40 MG TABLET
Brand
00597004037•Boehringer Ingelheim Pharmaceuticals Inc.
$4.5019
per EA
COZAAR 50 MG TABLET
Brand
78206012201•Organon LLC
$4.5110
per EA
COZAAR 50 MG TABLET
Brand
78206012202•Organon LLC
$4.5110
per EA
HYZAAR 50-12.5 TABLET
Brand
78206013901•Organon LLC
$5.0084
per EA
HYZAAR 50-12.5 TABLET
Brand
78206013902•Organon LLC
$5.0084
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy